All In Biotech

Drug Trial Radar · NCT02143466

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

344

Actual

Start

Aug 5, 2014

Primary completion

Mar 4, 2020

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer

Conditions

  • Advanced Non Small Cell Lung Cancer

Interventions

  • Part A - AZD9291 in combination with AZD6094Drug

    Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.

  • Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)Drug

    Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.

  • Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)Drug

    Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.

  • Part A - AZD9291 in combination with intermittent selumetinibDrug

    Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.

  • Part A - AZD9291 in combination with MEDI4736Drug

    Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B. Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.

  • Part B - AZD9291 in combination with AZD6094Drug

    Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.

  • Part B - AZD9291 in combination with selumetinibDrug

    Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.

  • Part B - AZD9291 in combination with MEDI4736Drug

    Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination. Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.

  • Part C - AZD6094 monotherapy (Japan only)Drug

    Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.

  • Part C - AZD9291 in combination with AZD6094 (Japan only)Drug

    Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.

  • Part D - AZD9291 in combination with AZD6094Drug

    Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinibTime frame: Adverse events will be collected from baseline until 28 days after the last dose in the AZD6094 or selumetinib arms.
  2. Number of participants with Adverse Events as a measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinibTime frame: Adverse events: baseline until 28 days after the last dose in the AZD6094 or selumetinib arms.

Locations

42 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Atlanta, Georgia

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    New York, New York

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Chūōku, Japan

  • Research Site

    Habikino-shi, Japan

  • Research Site

    Hirakata-shi, Japan

  • Research Site

    Kashiwa, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Gdansk, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Olsztyn, Poland

  • Research Site

    Poznan, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Cheongju-si, South Korea

  • Research Site

    Goyang-si, South Korea

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.